TBC1D3: A Potential Drug Target and Biomarker for the TBC1 Domain Family

Target Name: TBC1D3

NCBI ID: G729873

TBC1D3

TBC1D3: A Potential Drug Target and Biomarker for the TBC1 Domain Family

Introduction

The TBC1 (T cell browser) domain family is a conserved group of non-coding RNA molecules that play crucial roles in the regulation of cell proliferation, differentiation, and immune responses. The TBC1 domain contains several unique features that have led to its increased complexity and its diverse functions in various cellular processes. One of the TBC1 domain family members, TBC1D3, has been identified as a potential drug target and biomarker. This article will provide an overview of TBC1D3, its functions, and its potential as a drug target.

Overview of TBC1D3

TBC1D3 is a 21 kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is a part of the TBC1 domain family and is characterized by its unique structure, which consists of a long N-terminal alpha helix , a parallel beta-sheet, and a C-terminal TBC1-like domain.

The TBC1D3 protein is involved in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to provide oxygen and nutrients to tissues. TBC1D3 has been shown to promote the migration and invasion of cancer cells, which are crucial steps in the development of cancer.

In addition to its role in cell adhesion and migration, TBC1D3 has also been shown to play a role in the regulation of cell survival. Studies have shown that TBC1D3 can induce cell apoptosis, which is the process by which cells undergo programmed cell death. This process is crucial for the regulation of cellular aging and for the rejection of damaged or cancerous cells.

Potential Drug Target

TBC1D3 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the reasons for its potential as a drug target is its high, its ability to induce cell apoptosis, and its involvement in the regulation of angiogenesis.

The TBC1D3-based drug targeting strategies have been shown to be effective in various cellular models, including cancer cells, vascular smooth muscle cells, and airway epithelial cells. These strategies include small molecule inhibitors, RNA interference, and CRISPR/Cas9-based genome editing.

Biomarker Potential

TBC1D3 has also been identified as a potential biomarker for various diseases, including cancer. Its involvement in the regulation of cell apoptosis and its ability to induce cell apoptosis make it an attractive candidate for cancer biomarkers.

Studies have shown that TBC1D3 can be used as a biomarker for various types of cancer, including lung, breast, and colorectal cancers. In these studies, TBC1D3 has been shown to be expressed in various cancer cell types and has been used as a marker for the diagnosis and prognosis of cancer.

Conclusion

TBC1D3 is a unique protein that has been identified as a potential drug target and biomarker. Its functions in the regulation of cell adhesion, migration, and survival make it an attractive candidate for drug targeting strategies. Its potential as a biomarker for cancer makes it an important area of 閳ュ??濯焑search for the development of new diagnostic and therapeutic strategies.

Protein Name: TBC1 Domain Family Member 3

The "TBC1D3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets